Approximately 3-7% of non-small cell lung cancers (NSCLC) harbor an ALK gene fusion, thus defining a unique tumor group that may be responsive to targeted therapy. However, the method for diagnosis of ALK fusions has not been standardized. The breakpoint in ALK consistently occurs at exon 20 and EML4, although other fusion partners can also drive a strong expression of the ALK kinase domain. We have developed a rapid and accurate method for diagnosing ALK rearrangement in lung tumors by detecting the 5' and RT-PCR and 5' RACE coupling sequencing identified the fusion variants.
Introduction
ALK rearrangement represents a novel molecular target in a subset of non-small cell lung cancers (NSCLC) (1) .Fusion of ALK with the upstream partner, EML4, was found in NSCLC in 2007 (2) .This occurred due to chromosomal inversion on chromosome 2p, resulting in formation of the EML4-ALK fusion oncogene. Subsquently, other fusion variants and fusion partners, such as TFG (3) and KIF5B (4), have been identified. Notably, ALK rearrangements occur almost exclusively in adenocarcinomas (ADC) (5) . More recently, crizotinib (ALK inhibitor) has been recommended as first line systemic therapy for lung cancer patients with ALK rearrangements (6) . However, the method for detecting the fusion gene has not been standardized.
Several methods, including fluorescence in situ hybridization (FISH), reverse
transcription-polymerase chain reaction (RT-PCR) coupled with direct sequencing and immunohistochemistry (IHC) are currently used for detecting ALK rearrangements in cytology or tissue samples. However, each technique is associated with specific strengths and weaknesses for screening. Current clinical trials of crizotinib use FISH as the diagnostic method for detecting ALK rearrangements (7) . Unfortunately, FISH assay is a low-throughput assay requiring specialized technical resources and expertise and is thus not appropriate for detecting ALK rearrangements in large sample sizes. RT-PCR can define both ALK fusion partner and fusion variant, but cannot detect unknown ALK rearrangements. In addition, since there are a number of EML4-ALK variants and non-EML4-ALK fusions in NSCLCs, RT-PCR is not the optimal detection method.
Previously, IHC seemed not to be economical or efficient (4) . Unfortunately, ALK immune Recently, Exon Arrays examining expression levels of consecutive exons have been developed for detecting gene rearrangements (8) .The breakpoint in ALK consistently occurs at exon 20 with the oncogenic effect of ALK rearrangement in NSCLC being due to EML4 or other fusion partners driving expression of ALK kinase domain (exon 20 to 29), with subsequent constitutive activation (5) . In contrast, the remaining non-kinase region of ALK (exon 1 to 19) is not so expressed (8) . Thus, we designed primer sets to amplify 5' and 3' portions of ALK mRNA. If unbalanced ALK mRNA expression was seen, ALK rearrangement was assumed to exist. Compared with other techniques, this assay seems to offer higher sensitivity, reduced complexity and a new method for detection.
Materials and Methods

Specimen Collection
A total of 654 frozen NSCLC tissue samples and their corresponding paraffin-embedded tumor tissues, including 617 (94.3%) ADCs and 37 (5.7%) adenosquamous carcinomas (ASCs), were collected from Oct. 2007 to Jun. 2011, with written informed consents from all patients. Tumor was obtained as previously described (9 
Exon Array
Exon array was performed as previously reported (8) . mRNA was isolated using RNeasy Mini Kit (Qiagen, Valencia, CA, USA) as described by manufacturer's protocol. rRNA was first removed with RiboMinus Human Transcriptome Isolation (Invitrogen) and cDNA obtained by Whole Transcript Sense Target Labeling. cDNA was fragmented and biotin-labeled using Whole Transcript Terminal Labeling (Affymetrix). Biotinylated targets were hybridized onto Affymetrix HuEX-1.0 exon array analysis (Affymetrix, Santa Clara, CA) following manufacturer's protocol. Arrays were scanned on GeneChip scanner 3000 7G.
Mutational Analyses
Mutational status of EGFR (exons 18-22), KRAS (exons 2, 3), HER2 (exons 18-21) and BRAF (exons [11] [12] [13] [14] [15] were assessed with standard reverse transcription-PCR-coupled direct sequencing. For detection of EML4-ALK fusions, primers were designed to amplify all known fusion variants, using cDNA, as described previously (10) . 
5' RACE and RT-PCR
Samples having high expression in ALK kinase domain and positive for ALK FISH, but negative for EML4-ALK fusion genes, were subjected to 5'-RACE analysis. 5'-RACE was performed using SMARTerTM RACE cDNA Amplification Kit (Clontech, CA, USA) as 
Immunohistochemistry (IHC)
IHC staining was performed on 4 ȝm thick, formalin-fixed, paraffin-embedded tissue.
Heat-induced epitope retrieval was performed with 1 mM EDTA, pH 9.0 (Maixin, Fuzhou, china).Slides were treated with 3% hydrogen peroxide for 15 minutes to block endogenous peroxidase activity. Mouse monoclonal anti-human CD246 (1:50 dilution, clone: ALK1, DAKO) was applied and incubated for 120 minutes. Slides were washed in PBS, and detected with horse radish peroxidase (HRP) conjugated anti-mouse Envision+ kit (DAKO), followed by counterstaining with hematoxylin. ALK IHC scores were assigned as follows: 3+, strong staining intensity in >5% tumor cells; 2+, moderate staining intensity in >5% tumor cells; 1+, faint or weak staining intensity in >5% tumor cells; and 0, no staining. IHC scoring was performed by two pathologists. portion were eligible for detecting ALK expression. Results showed unbalanced ALK mRNA expression in only ALK fusion samples, which had a significantly higher expression in the 3' than in the 5' portion (Fig 1) .
Statistical analysis
Screening of ALK rearrangements by qRT-PCR assay in "pan-negative" tumor samples
According to previous reports, EGFR, KRAS, HER2, BRAF and ALK mutations are almost always mutually exclusive. To validate feasibility in a larger sample size, we included 177 "pan-negative" cases for screening of ALK rearrangements by qRT-PCR. Patient characteristics are summarized in Supplemental 
showed unbalanced expression in 5' and 3' portions of ALK mRNA and balanced expression in 137 of 177 (77.4%) (Fig.2) . The normalized 3' portion of ALK expression value ranged from 32.2 to 1573.7 (median value: 248.9) in samples with unbalanced and 0.45 to 11.8 (median value: 2.24) with balanced ALK expression. To confirm ALK rearrangements, all cases were subjected to ALK FISH and RT-PCR. Samples with unbalanced expression were confirmed positive for ALK FISH, while 137 tumors with balanced expression were negative (Fig.3) . ALK fusions existed in 36 of 617 (5.8%) ADCs and 10.8% (4 of 37) of ASCs. Two cases with unbalanced ALK expression were originally misdiagnosed and classified as ALK FISH-negative (cases 81 and 93). Because tumor content in case 81 was lower than 10%, the FISH result was misinterpreted, the original FISH analysis re-reviewed and was incorrect. Case 93 was an ASC. The cause of mis-diagnosis was due to only the ADC component being positive for ALK FISH.
According to the relative expression in 3' portion of ALK mRNA, NSCLCs could be divided into two subtypes: unbalanced ALK expression (relative expression in 3' portion higher than 32), and balanced expression (relative expression in 3' portion lower than 12). Even using 3' portion of ALK expression value of 12 as a diagnostic criteria, qRT-PCR showed 100% sensitivity and specificity for detecting ALK-rearranged tumors. Diagnostic accuracy then was re-evaluated using two sets of primers (amplified 5' and 3' portions, respectively). High sensitivity and specificity for detecting ALK-rearranged tumors was achieved setting diagnostic criteria at 32 (Supplemental Table 3 ). Therefore, criteria for detecting ALK-rearranged tumors by qRT-PCR was felt best set at 12 when multiple sets of primers were applied and 32 when only two sets were used in the validation set. There were also 
four cases found to be negative by RT-PCR but positive for FISH and qRT-PCR. Sensitivity of RT-PCR was 90 percent. ALK protein expression was detected in 90% of 40 ALK positive samples, which included scores of 0 (n=4), 1+ (n=6), 2+ (n=9) and 3+ (n=21) (Supplementary Figure 2) . Relative expression levels in 3' portion of ALK mRNA were significantly higher in samples with strong IHC staining than weak and moderate staining (665±106 vs 203.1 ± 67.7, p=0.002) ( Table 1) .
Influence of tumor content on relative expression in 3' portion of ALK transcripts
Tumor content of snap frozen specimens and relative expression in 3' portion of ALK mRNA are shown in Supplementary Figure 3 . There was a trend for tumor content more than 50% having a higher relative expression in 3' portion of ALK mRNA (328.7±374 vs 447.7±421.6), but without statistical significance (p=0.389). Of 7 ALK-positive samples with only 10% tumor content, the relative expression in 3' portion of ALK mRNA was 51.6-685 (median: 101.1).
Identification of novel KIF5B-ALK and EML4-ALK variants
Previously unidentified were 6 ALK fusion variants, including one KIF5B-ALK and five
EML4-ALK. Case 93 was positive for qRT-PCR and FISH but negative for RT-PCR, using
primers spanning between exon 20 of ALK and reported EML4-ALK variants. Therefore, 5'RACE and sequencing were performed. A novel KIF5B variant and a fusion consisting of an in-frame fusion between exon 17 of KIF5B and exon 20 of ALK were found, confirmed by RT-PCR (Fig.4A) . (Fig.4B) .
A novel isoform of EML4-ALK transcript with 53bp deletion in an original exon 10 was observed (case 988), mRNA splicing being referred to as exon 10b and the original exon 10 as exon 10a (Fig.4C) . Also identified were 3 novel EML4-ALK variants with 18bp (case 
Discussion
We performed this study to evaluate the potential role of qRT-PCR as a diagnostic method for ALK-rearranged lung cancers. Its importance in NSCLCs relates to the apparently high predictive value of the gene translocation with regard to tumor sensitivity to ALK inhibitors.
Fusion gene frequency is approximately 3%-7% (1), suggesting that over 90% of patients will not benefit from ALK inhibitors. Therefore, accurate and timely identification of such patients have important therapeutic implications.
We present a novel method for the diagnosis of lung cancers harboring ALK-rearrangements. By using a qRT-PCR assay to detect expression in 5' and 3' portions of ALK transcripts, a cohort of 177 "pan-negative" lung cancers were screened, of which 40 (22.6%) samples harboring ALK arrangements were found. High sensitivity and specificity were achieved when using multiple sets of primers, selecting the relative 3' portion of ALK expression value >12 as diagnostic. Therefore, qRT-PCR, alone, seems sufficient for diagnosis, pending finding new ALK fusion variants.
qRT-PCR offers high sensitivity,.suggesting that the greater relative expression in 3' portion of ALK mRNA has a high probability of representing an abnormal ALK gene. Currently, FISH, RT-PCR, and IHC are being evaluated for detecting ALK rearrangements. Although FISH is used for screening in clinical trials, it has limitations. As EML4-ALK results from a chromosomal inversion on chromosome 2p and because the two genes are normally only ~12 Mb apart, split signals may be subtle and easily overlooked (11) . Previously,, sensitivity varied between 93-and 98.6 percent (12) (13) (14) . ALK rearrangements are infrequent and thus considered low-throughput so that FISH is not suitable for detecting ALK rearrangements in large sample sizes. Because FISH requires specialized technical resources, (such as fluorescence microscope) and expertise, it is not readily available. IHC is a readily available diagnostic tool, with three specified antibodies for ALK (ALK1 (15), D5F3 (12), 5A4 (17) . Initial attempts to use ALK antibodies detecting ALK-rearranged tumors were disappointing (17) . However, more sensitive ALK antibodies and techniques enhanced IHC signals so that IHC sensitivity has greatly improved. For example, the tyramide amplification method (using antibody ALK1) improves the ability to detect from 40% to 80% of specimens defined by FISH (12) . By using IHC scoring, one report had a sensitivity of 
90%, suggesting IHC can be used for screening in surgically resected specimens (15) . We also used an ALK1 antibody (DAKO) in our initial screening attempts but some ALK rearranged tumors only displayed faint staining and a few wild type tumors were positive (Data not shown). These results showed that IHC may be promising but not optimal for screening.
qRT-PCR is rapid, simple, relatively high-throughput and inexpensive for detecting ALK rearrangement. This assay can be completed in 4 hours, with an easy-to-use protocol. Cost per patient is less than 10 dollars using SYBR Green PCR master mix (Applied Biosystems, USA). ALK FISH assays, however, require 2 days and at least $100 for each sample with V1,E13;A20, V2,E20;A20, V3a/b,E6a/b;A20.
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